权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Improved Treatment of Colorectal Cancer with CF10 Diversity Supplement

使用 CF10 多样性补充剂改善结直肠癌的治疗

基本信息

批准号：
10543218
负责人：
William H Gmeiner
金额：
$ 10.45万
依托单位：
DEEP CREEK PHARMA, LLC
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10543218
关键词：
Address Administrative Supplement Biochemical Businesses Cancer Model Cell Line Chemosensitization Clinical Clinical Research Colonic Neoplasms Colorectal Cancer Complement Development Development Plans Entrepreneurship Fluorouracil Fostering Funding Generations Goals Growth Laboratories Leucovorin MC38 Malignant neoplasm of liver Measures Mentors Minority Modeling Molecular Pharmaceutical Preparations Pharmacology Phase Physiology Polyethylene Glycols Polymers Pre-Clinical Model Preclinical Drug Development Rattus Regimen Research Personnel Resistance Schedule Small Business Technology Transfer Research Technical Expertise Technology Toxic effect Training Translational Research Translations Writing antitumor agent cancer cell career career development career networking clinical candidate clinical development colorectal cancer treatment fluoropyrimidine forest improved in vivo medical schools meetings metastatic colorectal mortality non-Native novel nucleoside analog pre-doctoral programs resistance factors skills tumor

项目摘要

Project Summary for Supplement to CA254834 This minority administrative supplement to CA254834 requests funds for training Charles Chidi Okechukwu in the translational objectives of the Phase 1 STTR project and developing new business development and entrepreneurial skills fir the candidate that will support company growth. The funded Phase 1 STTR project (CA254834) focuses on demonstrating that a novel FP polymer, CF10, displays improved activity in pre-clinical models of metastatic colorectal cancer (mCRC). Currently funded Aims are: i) Demonstrate CF10 inhibits CRC metastatic progression in an orthotopic colon tumor model; ad ii) Demonstrate improved anti-metastatic activity for CF10 in a rat syngeneic CRC liver met model. With supplement funding, Charles will investigate if CF10 will be effective in treating CRC with acquired resistance to 5-FU and will be potentiated in combination with leucovorin (LV; folinic acid), which complements ongoing studies. The supplemental Aims are: S1) Demonstrate improved anti-metastatic activity for CF10 in 5-FU-resistant orthotopic CRC models; and S2) Evaluate Leucovorin potentiation of CF10 in 5-FU-resistant orthotopic CRC models. The mentoring plan for Charles will include training in technical skills related to pre-clinical drug development, translational research, and entrepreneurship. Training will include interfacing with researchers, clinical experts, and with business development experts. Charles will also receive mentoring in writing skills, including business plan development, and presentation skills, including presentation to investors. Training will enhance the long-term career opportunities of the applicant, including development of a professional network, and advance the goals of the company in commercializing CF10 technology.

CA254834补充的项目总结 CA254834的这份少数民族行政补充申请资金，用于培训Charles Chidi Okechukwu，第1阶段STTR项目的转化目标和开发新业务，候选人的创业技能将支持公司的发展。资助的第一阶段STTR项目（CA 254834）着重于证明新型FP聚合物CF10在临床前治疗中显示出改善的活性。转移性结直肠癌（mCRC）模型。目前资助的目标是：i）证明CF10抑制CRC ad ii）显示改善的抗转移活性对于大鼠同系CRC肝脏Met模型中的CF 10。有了补充资金，查尔斯将调查CF10是否会有效治疗对5-FU具有获得性耐药性的CRC，并将与亚叶酸（LV;亚叶酸），它补充了正在进行的研究。补充目标是：S1）演示在5-FU-抗性原位CRC模型中改善CF10的抗转移活性;和S2）评估甲酰四氢叶酸增强CF10在5-FU耐药原位CRC模型中的作用。查尔斯的辅导计划将包括与临床前药物开发、转化研究相关的技术技能培训，创业培训将包括与研究人员，临床专家和企业的接口发展专家。查尔斯还将接受写作技巧方面的指导，包括商业计划的制定，和演讲技巧，包括向投资者的演讲。培训将提高长期的职业生涯申请人的机会，包括专业网络的发展，并推进的目标， CF10技术的商业化。